Evidence map›Paper›PMID 18421544›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2008

Rapid correction of low vitamin D status in nursing home residents.

R Przybelski, S Agrawal, D Krueger, J A Engelke, F Walbrun, N Binkley

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04115982 (Vitamin D3 in Sensory Recovery After Digital NERVe Suture), which is not on this map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04115982 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Vitamin D3 in Sensory Recovery After Digital NERVe Suture: a Randomized Controlled Trial.

TypeinterventionalSponsorUniversity Hospital, CaenRan2020 to 2022Enrolled72ConditionsDigital Nerve InjuryArmsCholecalciferol, Placebos
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. High-dose oral vitamin D3 supplementation in the elderly.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2009
    Trial
  11. Review
  12. Observational
  13. Is There a Role of Vitamin D in Alzheimer's Disease?CNS & neurological disorders drug targets · 2024
    Review
  14. Review
  15. Vitamin D in Neurological Diseases.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

R PrzybelskiUniversity of Wisconsin Osteoporosis Clinical Research Program, Madison, WI 53705, USA. rjprzybe@facstaff.wisc.edu
S Agrawal
D Krueger
J A Engelke
F Walbrun
N Binkley

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThis prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents.

introductionLow vitamin D status is common among nursing home residents and contributes to bone loss, falls and fractures. The objective of this study was to evaluate the efficacy and safety of short course, high dose, oral vitamin D(2) (ergocalciferol) treatment.

methodsThis prospective study included 63 nursing home residents. The 25 with low vitamin D status (serum 25(OH)D < or = 25 ng/ml) received oral ergocalciferol 50,000 IU three times weekly for four weeks; the others received no change to their routine care. Serum total 25(OH)D, 25(OH)D(2), 25(OH)D(3), calcium, parathyroid hormone (PTH), bone turnover markers and neuro-cognitive assessments were obtained at baseline and four weeks.

resultsMean total 25(OH)D concentration increased (p < 0.0001) from 17.3 to 63.8 ng/ml in the treated group and remained unchanged in the comparison group. Serum 25(OH)D(3) remained stable in the comparison group, but declined (p < 0.0001) with D(2) treatment from 15.4 to 9.1 ng/ml. Serum PTH trended down in the treatment group (p = 0.06). No treatment-induced improvement in ambulation, cognition or behavior was observed. No hypercalcemia or other adverse effects were observed with ergocalciferol treatment.

conclusionFour weeks of oral vitamin D(2) supplementation effectively and safely normalizes serum 25(OH)D in nursing home residents.

Indexed as

Nursing HomesAdultAgedAged, 80 and overBone Density Conservation AgentsCalciumDrug Administration ScheduleErgocalciferolsHomes for the AgedHumansMiddle AgedParathyroid HormoneProspective StudiesVitamin DVitamin D Deficiency25-hydroxyvitamin DBone Density Conservation AgentsCalciumErgocalciferolsParathyroid HormoneVitamin D

Identifiers

PMID18421544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.